|Dr. Sanjay S. Shukla||Pres, CEO & Director||460.08k||N/A||1972|
|Ms. Jill M. Broadfoot||Chief Financial Officer||361.59k||N/A||1962|
|Ms. Nancy E. Denyes Krueger||Gen. Counsel & Corp. Sec.||347.93k||N/A||1968|
|Xiang-Lei Yang Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Peter Villiger||VP of Corp. Devel.||N/A||N/A||N/A|
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for regulating immune engagement in interstitial lung diseases. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was founded in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.